Previous meta‐analysis proved that adjuvant treatment with EGFR‐TKIs can reduce the probability of tumor recurrence and prolong DFS with fewer adverse events,17, 20 indicating that they can provide an alternative option to adjuvant chemotherapy in patients with EGFR‐mutated NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.